KR20230041028A - SARS-CoV-2 면역원성 조성물, 백신 및 방법 - Google Patents

SARS-CoV-2 면역원성 조성물, 백신 및 방법 Download PDF

Info

Publication number
KR20230041028A
KR20230041028A KR1020237005288A KR20237005288A KR20230041028A KR 20230041028 A KR20230041028 A KR 20230041028A KR 1020237005288 A KR1020237005288 A KR 1020237005288A KR 20237005288 A KR20237005288 A KR 20237005288A KR 20230041028 A KR20230041028 A KR 20230041028A
Authority
KR
South Korea
Prior art keywords
cov
sars
seq
protein
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005288A
Other languages
English (en)
Korean (ko)
Inventor
삐에르 샤르노
민-웬 구
삐에르 오띠
니꼴라 에스끄리우
마릴린느 부르진느
라에 마예레씨
Original Assignee
앵스티띠 파스퇴르
떼라벡띠스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000293 external-priority patent/WO2022167831A1/en
Application filed by 앵스티띠 파스퇴르, 떼라벡띠스 filed Critical 앵스티띠 파스퇴르
Publication of KR20230041028A publication Critical patent/KR20230041028A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/544Mucosal route to the airways
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237005288A 2020-07-15 2021-07-15 SARS-CoV-2 면역원성 조성물, 백신 및 방법 Pending KR20230041028A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063052264P 2020-07-15 2020-07-15
US63/052,264 2020-07-15
US202063130202P 2020-12-23 2020-12-23
US63/130,202 2020-12-23
IBPCT/IB2021/000293 2021-02-02
PCT/IB2021/000293 WO2022167831A1 (en) 2021-02-02 2021-02-02 Sars-cov-2 immunogenic compositions, vaccines, and methods
PCT/EP2021/069890 WO2022013405A1 (en) 2020-07-15 2021-07-15 Sars-cov-2 immunogenic compositions, vaccines, and methods

Publications (1)

Publication Number Publication Date
KR20230041028A true KR20230041028A (ko) 2023-03-23

Family

ID=77104030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005288A Pending KR20230041028A (ko) 2020-07-15 2021-07-15 SARS-CoV-2 면역원성 조성물, 백신 및 방법

Country Status (8)

Country Link
US (1) US20230256084A1 (https=)
EP (1) EP4181954A1 (https=)
JP (1) JP2023535163A (https=)
KR (1) KR20230041028A (https=)
AU (1) AU2021308424A1 (https=)
BR (1) BR112023000730A2 (https=)
CA (1) CA3185952A1 (https=)
WO (1) WO2022013405A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117120085A (zh) * 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2023135439A1 (en) * 2022-01-17 2023-07-20 Institut Pasteur Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
EP4486378A1 (en) * 2022-03-02 2025-01-08 ISR Immune System Regulation Holding AB (publ) Vaccine composition comprising an antigen and a tlr3 agonist
PL442478A1 (pl) * 2022-10-10 2024-04-15 Politechnika Warszawska Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
PL247223B1 (pl) * 2022-10-10 2025-06-02 Politechnika Warszawska Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
WO2024091694A1 (en) * 2022-10-28 2024-05-02 Mary Hitchcock Memorial Hospital, For Itself And On Behalf Of Dartmouth-Hitchcock Clinic Chimeric human receptor for pathogenic viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
CA2627485C (en) * 2005-10-28 2017-02-21 Katsuyuki Mitomo Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein
RS53257B2 (sr) * 2009-07-24 2018-06-29 Immune Design Corp Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
AU2021308424A1 (en) 2023-02-09
EP4181954A1 (en) 2023-05-24
BR112023000730A2 (pt) 2023-10-03
WO2022013405A1 (en) 2022-01-20
JP2023535163A (ja) 2023-08-16
CA3185952A1 (en) 2022-01-20
US20230256084A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
KR20230041028A (ko) SARS-CoV-2 면역원성 조성물, 백신 및 방법
AU2016202122B2 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
KR102154225B1 (ko) Aav sflt-1을 사용한 amd의 치료
US20250135031A1 (en) Single-vector gene construct comprising insulin and glucokinase genes
KR102382942B1 (ko) B형 간염 바이러스 코어 단백질 및 표면 항원 단백질 및 이를 포함하는 백신
KR102805532B1 (ko) 최적화된 핵산 항체 작제물
KR102628872B1 (ko) 세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20230019450A (ko) 캡슐화된 rna 레플리콘 및 사용 방법
KR20230087583A (ko) 항원을 mhc-ii 경로로 전달하고 숙주에서 cd4+ 및 cd8+ t-세포 반응을 유도하는 새로운 세대의 렌티바이러스 벡터
CN116323942A (zh) 用于基因组编辑的组合物及其使用方法
KR102709250B1 (ko) 다중 말라리아 예비-적혈구 항원 및 이의 숙주내에서의 보호성 면역 반응의 유발에 있어서의 용도
CN117120085A (zh) Sars-cov-2免疫原性组合物、疫苗和方法
KR20230156394A (ko) Mhc-ii 경로에 대한 항원을 표적화하고 숙주에서 보호 cd8+ 및 cd4+ t 세포 면역성을 유도하는 렌티바이러스 벡터
KR102828669B1 (ko) 재조합 활성화 유전자 1 (rag1) 중증 복합 면역결핍증 (scid) 을 치료하기 위한 조혈 줄기 세포에서의 렌티바이러스 벡터
CA2974235C (en) Single-vector gene construct comprising insulin and glucokinase genes
HK40013238A (en) Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
HK1246318B (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240705

Comment text: Request for Examination of Application